Cardiogenic shock associated with acute myocard ial infarction, cardiomyopathy or myocarditis Cardiogenic shock
Conditions
Interventions
Set management targets for anticoagulation with unfractionated heparin. (aPTT ratio lower group 1.5-1.8, upper group 2.2-2.5)
D010314
Activated Partial Thromboplastin Time
Sponsors
Kasugai Daisuke
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Cases in which VA-ECMO was introduced to provide circulatory support for cardiogenic shock. Patients with cardiogenic shock with a background of acute myocardial infarction, cardiomyopathy or myocarditis.
Exclusion criteria
Exclusion criteria: Cases under 18 years of age. Cases of cardiac arrest in which there is a strong concern of hypoxic encephalopathy. (When any of the following (1) to (3) applies.) (1) Cases which the initial waveform is asystole. (2) Cases in which it takes more than 20 minutes from cardiac arrest to return of spontaneous circulation (ROSC) or introduction of VA-ECMO (3) Cases in which the pupillary reflex has disappeared. Cases with active bleeding and uncontrolled haemostasis or thrombosis at the time of enrolment. Cases in which withdrawal from VA-ECMO is already expected at the time of inclusion. Cases of cardiogenic shock due to septic cardiomyopathy. Cases of cardiomyopathy in the postpartum period. Perioperative cardiac surgery with open heart surgery. Cases of acute and chronic pulmonary thromboembolism and pulmonary hypertensive crisis. Heparin induced thrombocytopenia. Cases other than those listed above, where the clinician considers it inappropriate to allocate anticoagulant therapy, should be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hierarchical composite outcome of all-cause mortality, bleeding events (BARC criteria type 3 or type 5), thrombosis and total blood transfusion within 7 days after randomization. | — |
Secondary
| Measure | Time frame |
|---|---|
| All-cause mortality within 7 days, bleeding events within 7 days, thrombosis within 7 days, total blood transfusion within 7 days, all-cause mortality within 30 days, bleeding events within 30 days, thrombosis within 30 days, duration of VA-ECMO placement, duration of ICU stay. | — |
Contacts
Public ContactShingo Kazama
Nagoya University Hospital
Outcome results
None listed